Organogenesis HoldingsFRA:2PQ 66 Days Inventory is 102.10 as of Mar. 2026, which is 19% above its 10-year median of 85.89. GuruFocus rates FRA:2PQ with a GF Score™ of 66/100 and a GF Value™ of €2.71 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 916 Drug Manufacturers companies, Organogenesis Holdings ranks better than 85.26% on this metric.
The historical rank and industry rank for Organogenesis Holdings's Days Inventory or its related term are showing as below:
FRA:2PQ'
s Days Inventory Range Over the Past 10 Years
Min: 73.18 Med: 85.89 Max: 106
Current: 83.69
During the past 11 years, Organogenesis Holdings's highest Days Inventory was 106.00. The lowest was 73.18. And the median was 85.89.
FRA:2PQ's Days Inventory is ranked better than 85.26% of 916
companies
in the Drug Manufacturers industry
Industry Median: 164.43
vs FRA:2PQ: 83.69
Organogenesis Holdings's Days Inventory
declined
from Mar. 2025 (108.48) to Mar. 2026 (102.10).
Inventory Turnover measures how fast the company turns over its inventory within a year.
Organogenesis Holdings's Inventory Turnover for the
three
months ended in Mar. 2026 was 0.89.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Organogenesis Holdings's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 0.80.
Organogenesis Holdings (FRA:2PQ) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Organogenesis Holdings's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Organogenesis Holdings's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Organogenesis Holdings Days Inventory Related Terms
Organogenesis Holdings Days Inventory Historical Data
* Premium members only.
The historical data trend for Organogenesis Holdings's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:2PQ vs TKNO, AKBA, SIGA: Days Inventory Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Organogenesis Holdings's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Organogenesis Holdings Days Inventory vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Organogenesis Holdings's Days Inventory distribution charts can be found below:
* The bar in red indicates where Organogenesis Holdings's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Organogenesis Holdings (FRA:2PQ) has a Days Inventory of 102.10 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Organogenesis Holdings and its competitors. This is 19% above median its historical median of 85.89. Over the past decade, Organogenesis Holdings' Days Inventory has ranged from 73.18 to 106.00. According to the industry distribution chart, Organogenesis Holdings ranks #135 out of 916 companies in the Drug Manufacturers industry, placing it in the top 14.7%.
Is Organogenesis Holdings' Days Inventory too high?
Organogenesis Holdings' current Days Inventory of 102.10 is 19% above median its 10-year median of 85.89. Over the past 10 years, this metric has ranged from a low of 73.18 to a high of 106.00. The Drug Manufacturers industry median Days Inventory is 164.43. Organogenesis Holdings' value of 102.10 is 37.9% below this industry median. Based on the distribution chart, Organogenesis Holdings ranks #135 out of 916 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Organogenesis Holdings has a GF Score™ of 66/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Organogenesis Holdings' Days Inventory compare to TKNO and AKBA?
According to the Drug Manufacturers industry distribution chart, Organogenesis Holdings ranks #135 out of 916 companies for Days Inventory. This places Organogenesis Holdings in the top 15% of its industry — outperforming the majority of peers. The industry median Days Inventory is 164.43. Organogenesis Holdings' value of 102.10 is 37.9% below this benchmark. Historically, Organogenesis Holdings' own Days Inventory has ranged from 73.18 to 106.00 over the past decade. While the company's 10-year median is 85.89 vs. the industry median of 164.43, Organogenesis Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Drug Manufacturers company?
The median Days Inventory among Drug Manufacturers companies is 164.43, based on 916 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Organogenesis Holdings's current Days Inventory of 102.10 is 37.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Organogenesis Holdings and its competitors. For the Drug Manufacturers industry, the median Days Inventory is 164.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Organogenesis Holdings's current Days Inventory is 102.10, which is 19% above median its own 10-year median of 85.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Organogenesis Holdings stock overvalued right now?
Based on GuruFocus' analysis, Organogenesis Holdings (FRA:2PQ) is currently considered Modestly Undervalued. The stock's GF Value™ is €2.71, compared to a current price of €2.06 — trading 24% below its estimated fair value. The current Days Inventory is 102.10, which is 19% above median its 10-year median of 85.89 and 37.9% below the Drug Manufacturers industry median of 164.43. Organogenesis Holdings' overall GF Score™ is 66/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Organogenesis Holdings (FRA:2PQ), the current Days Inventory is 102.10 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Organogenesis Holdings (FRA:2PQ) Overvalued in 2026?
Based on GuruFocus' analysis, Organogenesis Holdings stock appears to be undervalued.
The current stock price of €2.06 is trading 24% below its estimated GF Value™ of €2.71.
GuruFocus considers Organogenesis Holdings to be Modestly Undervalued.
Key valuation signals for FRA:2PQ:
Days Inventory: 102.10 (19% above median its 10-year median of 85.89)
GF Value™: €2.71 vs. price of €2.06 (24% below fair value)
Industry Position: 37.9% below the Drug Manufacturers median (#135 of 916)
No single metric tells the full story. See the FRA:2PQ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.
66GF Score
Get the complete analysis for FRA:2PQ
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:2PQ has been successfully added to your 
